Publication: Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer
dc.contributor.coauthor | Topkan, Erkan | |
dc.contributor.coauthor | Özdemir, Yurday | |
dc.contributor.coauthor | Yıldırım, Berna A. | |
dc.contributor.coauthor | Güler, Ozan C. | |
dc.contributor.coauthor | Mertsoylu, Hüseyin | |
dc.contributor.coauthor | Hahn, Stephen M. | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Selek, Uğur | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T23:29:37Z | |
dc.date.issued | 2018 | |
dc.description.abstract | Purpose: We investigated the influence of change in hemoglobin (Hgb) levels during concurrent chemoradiotherapy (C-CRT) on outcomes of non-anemic patients with stage IIIA/B non-small cell lung cancer (NSCLC). Methods: We identified 722 patients with stage IIIA/B NSCLC without anemia at baseline [hemoglobin (Hgb) < 12 g/dL for women or < 13 g/dL for men], either nonsmokers or ex-smokers, who received C-CRT between 2007 and 2012. All patients had received 1 - 3 cycles of platinum-based doublet chemotherapy during radiotherapy to 60 - 66 Gy and had documented Hgb measurements before treatment and at weekly intervals for 6 weeks during the C-CRT. Potential associations were assessed between baseline, nadir, extent of change in Hgb level, and anemia and overall survival (OS), locoregional progression-free survival (LRPFS), and PFS. Results: The median baseline Hgb level was 13.9 g/dL (range 12.0-16.8) and declined to a median 12.4 g/dL (range 7.9-16.1) during treatment. Anemia appeared in 237 patients (32.8%) and was more common among women (44.8% vs. 26.5%, P < 0.001). Neither baseline Hgb level nor change during treatment nor anemia emergence influenced any survival endpoint. Receiver operating curve analysis revealed an Hgb nadir of 11.1 g/dL to be associated with outcomes, in that a nadir Hgb < 11.1 g/dL (in 156 patients) was linked with shorter median OS time (P < 0.001), LRPFS time (P < 0.001), and PFS time (P < 0.001); retained significance for all three endpoints in multivariate analyses; and was more strongly associated with OS in squamous cell carcinoma (P < 0.001) than in adenocarcinoma (P = 0.009). Conclusion: Nadir Hgb < 11.1 g/dL levels during C-CRT were associated with significantly poorer survival times in initially non-anemic patients presenting with locally advanced NSCLC. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.openaccess | NO | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 121 | |
dc.identifier.doi | 10.1016/j.lungcan.2018.04.016 | |
dc.identifier.eissn | 1872-8332 | |
dc.identifier.issn | 0169-5002 | |
dc.identifier.quartile | Q2 | |
dc.identifier.scopus | 2-s2.0-85046090795 | |
dc.identifier.uri | https://doi.org/10.1016/j.lungcan.2018.04.016 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/12077 | |
dc.identifier.wos | 436222300006 | |
dc.keywords | Anemia | |
dc.keywords | Chemoradiotherapy | |
dc.keywords | Nadir hemoglobin | |
dc.keywords | Stage Iiia/B non-small cell lung cancer | |
dc.keywords | Prognostic-factor | |
dc.keywords | Anemia | |
dc.keywords | Radiotherapy | |
dc.keywords | Carcinoma | |
dc.keywords | Erythropoietin | |
dc.keywords | Chemoradiation | |
dc.keywords | Therapy | |
dc.language.iso | eng | |
dc.publisher | Elsevier Ireland Ltd | |
dc.relation.ispartof | Lung Cancer | |
dc.subject | Oncology | |
dc.subject | Respiratory organs | |
dc.subject | Respiration | |
dc.title | Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Selek, Uğur | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |